Jerome Alan Grant, the Chief Executive Officer of $UTI, sold 60,040 shares of the company on 02-27-2026 for an estimated $2,098,494. We received data on the trade from a recent SEC filing. This was a sale of approximately 12.2% of their shares of this class of stock. Following this trade, they now own 430,215 shares of this class of $UTI stock.
$UTI Insider Trading Activity
$UTI insiders have traded $UTI stock on the open market 8 times in the past 6 months. Of those trades, 6 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $UTI stock by insiders over the last 6 months:
- CAPITAL MANAGEMENT, LLC COLISEUM has made 6 purchases buying 1,255,173 shares for an estimated $30,813,450 and 0 sales.
- JEROME ALAN GRANT (Chief Executive Officer) sold 60,040 shares for an estimated $2,098,494
- CAROLYN ANN FRANK (SVP/Chief HR Officer) sold 1,750 shares for an estimated $52,634
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$UTI Hedge Fund Activity
We have seen 122 institutional investors add shares of $UTI stock to their portfolio, and 168 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MACQUARIE GROUP LTD removed 1,265,713 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $33,073,080
- COLISEUM CAPITAL MANAGEMENT, LLC added 1,255,173 shares (+46.2%) to their portfolio in Q4 2025, for an estimated $32,797,670
- THRIVENT FINANCIAL FOR LUTHERANS added 1,140,465 shares (+132.9%) to their portfolio in Q4 2025, for an estimated $29,800,350
- PERRITT CAPITAL MANAGEMENT INC removed 902,386 shares (-97.2%) from their portfolio in Q3 2025, for an estimated $29,372,664
- POINT72 ASSET MANAGEMENT, L.P. added 813,150 shares (+493.5%) to their portfolio in Q4 2025, for an estimated $21,247,609
- PRICE T ROWE ASSOCIATES INC /MD/ added 631,070 shares (+65.2%) to their portfolio in Q4 2025, for an estimated $16,489,859
- NUVEEN, LLC added 625,102 shares (+168.8%) to their portfolio in Q4 2025, for an estimated $16,333,915
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$UTI Revenue
$UTI had revenues of $220.8M in Q1 2026. This is an increase of 9.64% from the same period in the prior year.
You can track UTI financials on Quiver Quantitative's UTI stock page.
$UTI Analyst Ratings
Wall Street analysts have issued reports on $UTI in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barrington Research issued a "Outperform" rating on 01/21/2026
- Rosenblatt issued a "Buy" rating on 11/20/2025
To track analyst ratings and price targets for $UTI, check out Quiver Quantitative's $UTI forecast page.
$UTI Price Targets
Multiple analysts have issued price targets for $UTI recently. We have seen 2 analysts offer price targets for $UTI in the last 6 months, with a median target of $36.0.
Here are some recent targets:
- Steve Frankel from Rosenblatt set a target price of $36.0 on 02/05/2026
- Alexander Paris from Barrington Research set a target price of $36.0 on 02/05/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
